246 F. Supp. 3d 1024
D. Del.2017Background
- Plaintiffs Impax, AstraZeneca UK (AZUK), and AstraZeneca AB (AZAB) sued Lannett for infringement of U.S. Pat. Nos. 6,750,237 and 7,220,767 (Dearn patents), which claim zolmitriptan nasal formulations (Zomig nasal spray). Defendants stipulated to infringement of the asserted claims.
- Dispute centered on (1) standing/ownership of patent interests among AZUK/AZAB/Impax and (2) invalidity defenses: anticipation (Chauveau, Marquess) and obviousness over the prior art.
- AZAB is the named assignee on the patents; AZUK assigned UK application rights to AZAB in 2000. A 2002 Patent Administration agreement reserved unspecified "beneficial ownership" to AZUK; a 2012 license was executed between AZUK and Impax. Plaintiffs submitted a declaration from Amy Allen (AstraZeneca) to explain ownership/licensing.
- Prior art: Chauveau (oral/oromucosal formulations including triptans, discloses broad pH ranges and mentions zolmitriptan); Marquess (PCT application disclosing intranasal delivery generally but not zolmitriptan in the claimed sense or a specific pH); Tepper & Rapoport review (mentions nasal zolmitriptan in development).
- Key scientific fact: zolmitriptan produces a potent active metabolite (183C91) via first-pass hepatic metabolism; nasal administration bypasses liver and alters metabolite formation. This informed both obviousness and teaching-away analyses.
Issues
| Issue | Plaintiffs' Argument | Defendants' Argument | Held |
|---|---|---|---|
| Standing / ownership | AZAB is assignee; AZAB consented to Impax’s exclusive license; Allen declaration shows no other assignments | Plaintiffs failed to prove exact ownership chain; possible unrepresented owner (AZUK) means no standing | Court provisionally credited Allen, found sufficient showing that AZAB assigned and licensed rights to Impax and that plaintiffs have standing; allowed defendants one week to request live testimony to revisit ruling |
| Admissibility of Allen declaration | Declaration is permissible and necessary to resolve standing given parties did not treat standing as trial issue | Too-late evidence, unfair without cross-exam; prior deposition statements undermine Allen | Court admitted the declaration provisionally, denied strike motion, offered a live hearing if defendants request one within one week |
| Anticipation (35 U.S.C. §102) | Prior patents (Chauveau; Marquess) disclose zolmitriptan nasal formulations and pH ranges overlapping claimed pHs | Chauveau does not disclose zolmitriptan specifically arranged with the claimed pH; Marquess does not disclose zolmitriptan as claimed nor a specific pH | Court held defendants failed to prove anticipation: Chauveau’s broad pH ranges and lack of direct link to zolmitriptan are insufficient; Marquess fails to disclose the claimed zolmitriptan form/pH |
| Obviousness (35 U.S.C. §103) | A skilled artisan would have tried a nasal formulation and pH choices (e.g., based on sumatriptan/Remington); pH, buffer, sterility, packaging are routine | Prior art taught away from nasal zolmitriptan because its efficacy depends on an active hepatic metabolite; no reason/motivation with reasonable expectation of success to combine teachings | Court found clear-and-convincing standard not met: teaching-away (role of metabolite) and expert credibility favored plaintiffs; secondary considerations (licensing) support nonobviousness though commercial-success evidence was mixed |
Key Cases Cited
- Lujan v. Defenders of Wildlife, 504 U.S. 555 (standing is jurisdictional under Article III)
- Abraxis Bioscience, Inc. v. Navinta LLC, 625 F.3d 1359 (Fed. Cir.) (patent standing typically requires legal title)
- Textile Prods., Inc. v. Mead Corp., 134 F.3d 1481 (Fed. Cir.) (divided ownership—need all owners as plaintiffs)
- Callaway Golf Co. v. Acushnet Co., 576 F.3d 1331 (Fed. Cir.) (anticipation requires every claim element arranged as in the claim)
- Net MoneyIN Inc. v. VeriSign, Inc., 545 F.3d 1359 (Fed. Cir.) (anticipation requires prior invention and elements arranged as claimed)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (obviousness framework; avoid hindsight and require motivation/expectation of success)
- In re Cyclobenzaprine Hydrochloride, 676 F.3d 1063 (Fed. Cir.) (limits on obvious-to-try; finite predictable options required)
- W. L. Gore & Assocs., Inc. v. Garlock, 721 F.2d 1540 (Fed. Cir.) (teachings in prior art that diverge or teach away support nonobviousness)
- Atofina v. Great Lakes Chem. Corp., 441 F.3d 991 (Fed. Cir.) (broad ranges in prior art do not necessarily anticipate narrow claim limitations)